SciELO - Scientific Electronic Library Online

vol.80 issue6Development of an Acute Myocardial Infarction Risk Adjustment Model for Spain: Comparison to the Charlson Model and the ICES Model. Application for Gauging Care ResultsPower Relations and Democracy in Health Councils in Brazil: a Case Study author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google


Revista Española de Salud Pública

On-line version ISSN 2173-9110Print version ISSN 1135-5727


CONGET DONLO, Ignacio et al. Cost-Utility Analysis of Iinsulin Pumps Compared to Multiple Daily doses of Insulin in Patients with Type 1 Diabetes Mellitus in Spain. Rev. Esp. Salud Publica [online]. 2006, vol.80, n.6, pp.679-695. ISSN 2173-9110.

Background: The use of continuous subcutaneous insulin infusion (CSII) for treating Type I diabetes mellitus (DM1) has been related to better metabolic control compared it to daily multiple insulin injections (DMI) and thus to a lowering of the related costs. However, this therapy is now being used to a lesser extent due, at least partially, to the higher initial cost of purchase. This study is aimed at estimating the clinical and economic consequences of using CSII as compared to DMI by means of a cost-utility analysis. Methods: A mathematical simulation model was adapted using nationwide clinical and economic data to simulate the long-term clinical and economic consequences for a DM1 patient. The time horizon was the patient's lifetime, including only direct healthcare costs and updating both costs and benefits at an annual 3% rate. Results: In the basecase, the patients treated using CSII gained 0.890 years (p<0.05) and 0.852 QALYs (p<0.05). CSII treatment gives rise to an incremental average cost of 25,523 € (p<0.05) per patient treated, which gave us an incremental cost- utility ratio of 29,947 €/QALY [CI 95% (29,519; 30,375)]. Conclusions: The improvement in the glucose control among those patients treated using CSII was related to an overall lower cost in the handling of DM1 patients, which was found to have a favourable cost-utility ratio in comparison to conventional MDI treatment.

Keywords : Diabetes Mellitus Type 1; Cost-utility; Insulin pump; Programmable implantable; Economic model.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License